TW207998B - - Google Patents

Info

Publication number
TW207998B
TW207998B TW081101914A TW81101914A TW207998B TW 207998 B TW207998 B TW 207998B TW 081101914 A TW081101914 A TW 081101914A TW 81101914 A TW81101914 A TW 81101914A TW 207998 B TW207998 B TW 207998B
Authority
TW
Taiwan
Application number
TW081101914A
Other languages
Chinese (zh)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of TW207998B publication Critical patent/TW207998B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW081101914A 1991-03-28 1992-03-13 TW207998B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67691991A 1991-03-28 1991-03-28

Publications (1)

Publication Number Publication Date
TW207998B true TW207998B (en) 1993-06-21

Family

ID=24716565

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081101914A TW207998B (en) 1991-03-28 1992-03-13

Country Status (19)

Country Link
EP (1) EP0582643A1 (en)
JP (1) JPH06500793A (en)
CN (1) CN1065269A (en)
AU (1) AU658887B2 (en)
BR (1) BR9205810A (en)
CA (1) CA2107104A1 (en)
CZ (1) CZ387092A3 (en)
DE (1) DE9290035U1 (en)
FI (1) FI934222A (en)
HU (1) HUT67836A (en)
IE (1) IE920979A1 (en)
IL (1) IL101325A0 (en)
MX (1) MX9201414A (en)
NZ (1) NZ242152A (en)
PT (1) PT100301A (en)
TW (1) TW207998B (en)
WO (1) WO1992017446A2 (en)
YU (1) YU30392A (en)
ZA (1) ZA922238B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60204611T2 (en) * 2001-02-28 2006-05-11 Pfizer Products Inc., Groton Sulfonyl-pyridazinone derivatives for use as aldose reductase inhibitors
SE0100873D0 (en) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
AU2002226634B2 (en) 2001-03-30 2007-01-25 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
CN111617072B (en) * 2019-02-27 2023-06-20 苏州凯祥生物科技有限公司 Hyperuricemia medicine composition and medicine for treating hyperuricemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0676391B2 (en) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド Process for producing oxophthalazinyl acetic acid having heterocyclic side chain such as benzothiazole
FR2647676A1 (en) * 1989-06-05 1990-12-07 Union Pharma Scient Appl New pyridazinone derivatives, processes for preparing them and medicaments containing them which are useful, in particular, as aldose reductase inhibitors

Also Published As

Publication number Publication date
CZ387092A3 (en) 1994-02-16
JPH06500793A (en) 1994-01-27
ZA922238B (en) 1993-09-27
EP0582643A1 (en) 1994-02-16
HUT67836A (en) 1995-05-29
PT100301A (en) 1993-06-30
FI934222A0 (en) 1993-09-27
AU658887B2 (en) 1995-05-04
CA2107104A1 (en) 1992-09-29
BR9205810A (en) 1994-06-28
WO1992017446A3 (en) 1992-11-26
HU9302728D0 (en) 1993-12-28
FI934222A (en) 1993-09-27
NZ242152A (en) 1994-07-26
WO1992017446A2 (en) 1992-10-15
YU30392A (en) 1994-11-15
AU1779692A (en) 1992-11-02
IL101325A0 (en) 1992-11-15
IE920979A1 (en) 1992-10-07
DE9290035U1 (en) 1993-11-18
MX9201414A (en) 1992-10-01
CN1065269A (en) 1992-10-14

Similar Documents

Publication Publication Date Title
DK0616505T3 (en)
DE4291719T1 (en)
EP0524030A3 (en)
DE4290032T1 (en)
DE4292221T1 (en)
TW207998B (en)
DK0545490T3 (en)
JPH0498721U (en)
AU8357291A (en)
ECSM91556U (en)
ECSDI910046S (en)
DK77391D0 (en)
EP0507211A3 (en)
EP0521616A3 (en)
CN3009759S (en)
CN3009741S (en)
EP0495509A3 (en)
EP0496108A3 (en)
EP0499403A3 (en)
EP0500398A3 (en)
EP0501617A3 (en)
EP0504737A3 (en)
EP0504743A3 (en)
EP0505158A3 (en)
AU8792891A (en)